The quality of life among hepatocellular carcinoma patients receiving transarterial chemoembolization or TACE in each time period was varied and was affected by various internal and external factors. This descriptive research aimed to compare the quality of life among hepatocellular carcinoma patients between receiving 1-3 TACE sessions and 4-5 TACE sessions. Data were collected at a university hospital in southern Thailand, from November 2017 to June 2019. Sixty-five hepatocellular carcinoma patients receiving TACE were recruited, with a total of 293 sessions. Consequently, data were obtained for 6 times, from a period of before receiving initial TACE and after receiving TACE 1 to 5 sessions. Research instruments included the EORTC QLQ-C30 and QLQ-HCC18. The Cronbach’s alphas for the EORTC QLQ-C30 and QLQ- HCC18 questionnaires were 0.79 and 0.80, respectively. Data were analyzed using Paired t-test and descriptive statistics. Results show that: (1) The level of overall quality of life of hepatocellular carcinoma patients receiving 1-3 TACE sessions and 4-5 TACE sessions was at a good level and higher than the period of before receiving initial. (2) The mean score for overall quality of life of hepatocellular carcinoma patients between receiving 1-3 TACE sessions and 4-5 TACE sessions was not significant difference. The results showed that TACE treatment for hepatocellular carcinoma patients can improve the overall quality of life, although it has affected on every aspects of the quality of life.